✨ Free AI Report
Insilico Medicine: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Insilico Medicine
Company Research

Insilico Medicine: Business Overview, Financials & Competitive Analysis

Insilico Medicine scores 9/10 on the AskCyborg Cyborg Score (Exceptional). Market-validated AI drug discovery platform with $5.25B+ in partnership commitments and clinical-stage assets demonstrates execution capability and establishes Insilico as the leading generative AI-driven biotech player. Insilico Medicine has been named to Fast Company's prestigious list of the World's Most Innovative Companies and the #3 Most Innovative Biotech Company of.

What is Insilico Medicine's industry? Insilico Medicine (insilico.com) operates in Clinical AI & Drug Discovery. AskCyborg classifies Insilico Medicine under Clinical AI & Drug Discovery in its company registry.

Insilico Medicine is a clinical-stage generative artificial intelligence (AI)-driven drug discovery company that uses genomics, big data analysis, and deep learning for in silico drug discovery. The company was listed...

9/ 10Exceptional

Cyborg Score thesis

Market-validated AI drug discovery platform with $5.25B+ in partnership commitments and clinical-stage assets demonstrates...

Read the full analyst-debate transcript →
Industry Clinical AI & Drug Discovery
4 named competitors
5 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Insilico Medicine Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Insilico Medicine

AskCyborg analysts argue the bull and bear cases for Insilico Medicine across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Insilico Medicine OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Insilico Medicine Overview

Pro stress-test →

Insilico Medicine is a clinical-stage generative artificial intelligence (AI)-driven drug discovery company that uses genomics, big data analysis, and deep learning for in silico drug discovery. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code HKEX: 03696. The company has achieved significant commercial momentum through landmark partnerships and clinical progress with its proprietary Pharma.AI platform.

Strategic Profile

Pro stress-test →

Insilico continues to drive deep integration of cutting-edge AI technology with extensive scientific expertise, building a diversified internal pipeline covering over 40 innovative programs and 28 drug candidates at the IND-enabling stage, of which 12 have received IND clearance. The company operates a diversified business model spanning software licensing to leading pharma, out-licensing deals, and AI-enabled drug discovery collaborations, positioning it as a bridge between Big Pharma and AI-driven innovation in therapeutic development.

Competitive Landscape

Pro stress-test →

BenevolentAI is among Insilico Medicine's competitors in the AI-driven drug discovery space. Insilico differentiates through its proprietary Pharma.AI platform spanning target validation to molecule optimization, clinical-stage proof-of-concept with rentosertib, and demonstrated ability to secure partnerships with top-20 pharma companies. The company's dual-purpose target identification (addressing both disease and aging) positions it uniquely in the emerging longevity biotech market.

Industry Context

Insilico Medicine operates in Clinical AI & Drug Discovery.

Key facts

Founded: 2014 · Headquarters: Boston, Massachusetts (with operations in Hong Kong and Abu Dhabi) · Employees: 317 · Revenue: $56.2M · Market cap: $2.79B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Insilico Medicine.

  • In early 2026, Insilico achieved multi-billion dollar out-licensing momentum, with an Eli Lilly agreement signed in March 2026 valued at $2.75 billion, including an upfront payment of $115 million.
  • In June 2026, Insilico announced a record-breaking $2.5 billion global R&D collaboration with SK Biopharmaceuticals to develop central nervous system treatments, covering neuroimmune disorders.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Qilu Pharmaceutical cardiometabolic collaboration worth ~$120M
  • March 2026Eli Lilly AI drug discovery partnership valued at $2.75B
  • +3 moreTrack every material event for Insilico Medicine as it happens. Explore monitoring →
Get alerted when Insilico Medicine has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BenevolentAIAI-powered drug discovery platform→ExscientiaAI-designed therapeutic compounds→DeepMind AlphaFoldProtein structure prediction for drug design→Lilly Drug DiscoveryLarge pharma partner with AI integration→

Compare Insilico Medicine with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Insilico Medicine operates in Clinical AI & Drug Discovery. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical AI & Drug Discovery research →
NEW · MCP server

Ask your AI assistant about Insilico Medicine

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Insilico Medicine and its top competitor on Cyborg Score”
“What did Insilico Medicine do this quarter?”
“Is Insilico Medicine a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Insilico Medicine do?+
Insilico Medicine is a clinical-stage generative artificial intelligence (AI)-driven drug discovery company that uses genomics, big data analysis, and deep learning for in silico drug discovery. The company was listed...
What is Insilico Medicine's Cyborg Score?+
Insilico Medicine has a Cyborg Score of 9/10 (Exceptional). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Insilico Medicine's main competitors?+
Named competitors include BenevolentAI, Exscientia, DeepMind AlphaFold, Lilly Drug Discovery. The full competitive landscape is in the AskCyborg report.
How can I get the full Insilico Medicine research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Insilico Medicine research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Insilico Medicine over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.